Clinical Trial Update: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of lazertinib and tepotinib for EGFR-mutant metastatic non-small cell lung cancer with MET overexpression or amplific…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)
• Tepotinib (tepotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-Small Cell Lung Cancer Metastatic | Phase 2 | Status: RECRUITING